Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2007-02-20
2007-02-20
Whiteman, Brian (Department: 1635)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C435S325000, C435S456000, C435S372000
Reexamination Certificate
active
10725013
ABSTRACT:
The present invention relates to methods and compositions for treatment of cardiovascular and peripheral vascular diseases using ex vivo and in vivo gene delivery technologies. One aspect of the present invention relates to a method for treating a vascular disease by introducing a DNA sequence encoding a TM protein or its variant into a segment of a blood vessel ex vitro using a gutless adenovirus vector. Another aspect of the present invention is to provide a method to deliver a gutless adenovirus vector carrying a DNA sequence encoding a TM protein or its variant using a stent.
REFERENCES:
patent: 4826811 (1989-05-01), Sehgal et al.
patent: 5981225 (1999-11-01), Kochanek et al.
patent: 6290949 (2001-09-01), French et al.
Kibbe et al. (J. Vasc. Surg. 34: 156-65, 2001).
He et al. (PNAS, 95: 2509-2514).
Brian S. Zuckerbraun et al., “Vascular Gene Therapy, A Reality of the 21stCentury,” Arch. Surg. 137:854-61 (2002).
Melina R. Kibbe et al., “Gene Therapy for Restenosis,” Circ. Res. 86:829-33 (2000).
Larry L. Shears et al., “Efficient Inhibition of Intimal Hyperplasia by Adenovirus-Mediated Inducible Nitric Oxide Synthase Gene Transfer to Rats and PigsIn Vivo,” J. Am. Coll. Surg., 187(3):295-306 (1998).
Russell Ross, “The pathogenesis of atherosclerosis: a perspective for the 1990s,” Nature, 362:801-9 (1993).
J. Evan Sadler, “Thrombomodulin Structure and Function,” Tehomb Haemost., 78:392-5 (1997).
Charles T. Esmon, “Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface,” Faseb J., 9:946-55 (1995).
Veikko Salomaa et al., “Soluble thrombomodulin as a predicctor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study,” Lancet, 353:1729-34 (1999).
R.M.J. Palmer et al., “Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor,” Nature, 327:524-6 (1987).
P. Kubes et al., “Nitric oxide: An endogenous modulator of leukocyte adhesion,” Proc. Natl. Acad. Sci. USA, 88:4651-5 (1991).
P. Gabriel Steg M.D., et al., “Reduction of Restenosis After Angioplasty in an Atheromatous Rabbit Model by Suicide Gene Therapy,” Circulation, 96:401-11 (1997).
Eric Van Belle et al., “Accelerated Endothelialization by Local Delivery of Recombinant Human Vascular Endothelial Growth Factor Reduces In-Stent Intimal Formation,” Biochem. and Biophs. Res. Communications, 235 311-6 (1997).
A. Neil Salyapongse, M.D., et al., “Gene Therapy and Tissue Engineering,” Tissue Engineering, 26(4):663-76 (1999).
T. Kon et al., “Bone Morphogenetic Protein-2-Stimulates Differentiation of Cultured Spinal Ligament Cells from Patients with Ossification of the Posterior Longitudinal Ligament,” Calcif. Tissue Int. (1997) 60:291-6.
Sehgal Lakshman R.
Wong Jonathan
LandOfFree
Ex vivo and in vivo expression of the thrombomodulin gene... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ex vivo and in vivo expression of the thrombomodulin gene..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ex vivo and in vivo expression of the thrombomodulin gene... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3874016